Regeneron Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 12:30PM GMT
Akash Tewari - Jefferies LLC, Research Division - Equity Analyst

Good morning, everyone. For those who just got back from ASCO, I feel sorry for you. I'm exhausted as well. But this is day 1 of our Jefferies Healthcare Conference, something that I am just really excited about, and I have the pleasure of hosting Regeneron, and I'm going to hand it off to Ryan for some brief introductions and forward-looking statements, and then we'll get into some questions.

Ryan Crowe - Regeneron Pharmaceuticals, Inc. - VP of IR

Thanks, Akash, and thanks for having us here at the Jefferies conference. It's always well attended, and I'm excited to be here. I'll start off with some forward-looking statement disclosures. I'd like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron's SEC

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot